Molecular mechanisms of action of ribavirin

J. L. Patterson, R. Fernandez-Larsson

Research output: Contribution to journalArticle

222 Citations (Scopus)

Abstract

Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.

Original languageEnglish (US)
Pages (from-to)1139-1146
Number of pages8
JournalReviews of Infectious Diseases
Volume12
Issue number6
StatePublished - 1990
Externally publishedYes

Fingerprint

Ribavirin
Antiviral Agents
HIV
Lassa Fever
Lassa virus
Hantaan virus
Respiratory Syncytial Viruses
United States Food and Drug Administration
Infection
Orthomyxoviridae
Aerosols
Acquired Immunodeficiency Syndrome
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Patterson, J. L., & Fernandez-Larsson, R. (1990). Molecular mechanisms of action of ribavirin. Reviews of Infectious Diseases, 12(6), 1139-1146.

Molecular mechanisms of action of ribavirin. / Patterson, J. L.; Fernandez-Larsson, R.

In: Reviews of Infectious Diseases, Vol. 12, No. 6, 1990, p. 1139-1146.

Research output: Contribution to journalArticle

Patterson, JL & Fernandez-Larsson, R 1990, 'Molecular mechanisms of action of ribavirin', Reviews of Infectious Diseases, vol. 12, no. 6, pp. 1139-1146.
Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Reviews of Infectious Diseases. 1990;12(6):1139-1146.
Patterson, J. L. ; Fernandez-Larsson, R. / Molecular mechanisms of action of ribavirin. In: Reviews of Infectious Diseases. 1990 ; Vol. 12, No. 6. pp. 1139-1146.
@article{79aecdfdd47247b0a3887c71d2af93f0,
title = "Molecular mechanisms of action of ribavirin",
abstract = "Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.",
author = "Patterson, {J. L.} and R. Fernandez-Larsson",
year = "1990",
language = "English (US)",
volume = "12",
pages = "1139--1146",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Molecular mechanisms of action of ribavirin

AU - Patterson, J. L.

AU - Fernandez-Larsson, R.

PY - 1990

Y1 - 1990

N2 - Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.

AB - Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.

UR - http://www.scopus.com/inward/record.url?scp=0025203460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025203460&partnerID=8YFLogxK

M3 - Article

C2 - 2267489

AN - SCOPUS:0025203460

VL - 12

SP - 1139

EP - 1146

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -